In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.

The stock's fall snapped a two-day winning streak.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

This was the stock's second consecutive day of gains.

We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at ...

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

Over the past month, shares of this HIV and hepatitis C drugmaker have returned +1.9%, compared to the Zacks S&P 500 composite's -3.3% change. During this period, the Zacks Medical - Biomedical and ...

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...

The stock trailed the S&P 500 ... The Zacks Consensus EPS estimate has moved 2.15% higher within the past month. Currently, Gilead Sciences is carrying a Zacks Rank of #3 (Hold). Looking at valuation, ...

On Tuesday, RBC Capital Markets adjusted its price target on Gilead Sciences stock, listed on NASDAQ:GILD, bringing it down slightly from $84.00 to $83.00. Despite the price target reduction ...

This decline was largely attributed to the $3.9 billion acquisition of CymaBay Therapeutics, Inc. In the past year, the stock is up by over 10.5%, which makes GILD one of the best dividend stocks ...